New perspectives on rheumatoid arthritis.
Rheumatoid arthritis (RA) remains one of the most common, puzzling and poorly treated diseases of humans. However, a surge of interest in the biology of chronic inflammation and in the design of more-potent and specific inhibitors of pro-inflammatory pathways heralds an optimistic era for the treatment of RA. A recent symposium provided a multidisciplinary perspective on the current status of such studies.
Reid Rheumatology Laboratory, Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
I
I
Wicks
G
G
McColl
L
L
Harrison
D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis; D012217:Rheumatoid Factor / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology
D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D018124:Receptors, Tumor Necrosis Factor; D012217:Rheumatoid Factor